LeReve Regenerative Wellness
- PRP Therapy
- IV Therapy
- Acne Treatment
- Arthritis Treatment
- Peptide Therapy
San Jose, CA
Stem-cell therapy in San Jose splits along real corridors. Interventional and research-adjacent rooms sit nearer Diridon / downtown research-adjacent suites. Cash-pay longevity menus cluster on Santana Row / Valley Fair storefronts. Willow Glen and Almaden corridor rooms catch the same label with different tissue sources.
Same "stem cell" label can mean same-day bone marrow or adipose product, a birth-tissue marketing pitch, or an investigational protocol. Those products are not interchangeable. California SB 1004 (2017) requires written disclosure when a provider offers non-FDA-approved stem cell therapies.
This hub lists Directory clinics for San Jose and stem-cell therapy. Inclusion is not an endorsement. Listing order is not paid ranking. Regenerated.com is free for patients. Featured slots stay labeled; Verified means credential checks, not spend.
Ask tissue or cell source, same-day autologous vs allogeneic, who performs the procedure, imaging guidance, what outcomes they track, how adverse events are handled, and whether the marketing matches FDA product category. Campbell and Santa Clara show up as drive time for some patients. Stanford / UCSF name-drop on a brochure is geography only. Prefer plain risk talk. Use the national stem-cell Directory and Guide, then return here.
Before you trust badges or counts on this page, read How to read a Regenerated city hub and Featured vs Verified vs organic. Then return here for local listings.
Regulatory context
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.
Available here
Nationwide
Stem Cell Therapy clinics across the US